Product information
Price | €175, €275, €395 |
---|---|
Size | 20 µl/µg | 50 µl/µg | 100 µl/µg |
Short name | LATS1/2 Antibody |
Host | Rabbit |
Isotype | IgG |
Target protein | LATS1 |
Recommended applications | ELISA, IHC-p, WB |
Reactivity | Human, Mouse |
Immunogen | The antiserum was produced against synthesized peptide derived from human LATS1/2. AA range:1041-1090 |
Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Formulation | Liquid in PBS containing 50% glycerol; 0.5% BSA and 0.02% sodium azide. |
Storage | -20°C for 1 year |
Product code | MB-AP10018 |
Additional information
Prev
Next
Serine/threonine-protein kinase LATS1/2 encoded by LATS1 is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatments. Two protein-coding transcripts and one non-protein coding transcript have been found for this gene.
LATS1, WARTS, Serine/threonine-protein kinase LATS1, Large tumor suppressor homolog 1, WARTS protein kinase, h-warts, LATS2, KPM, Serine/threonine-protein kinase LATS2, Kinase phosphorylated during mi
Human: O95835/Q9NRM7
Human: 9113/26524, Mouse: 16798/50523